Bavarian Nordic posts positive pre-clinical trial data for Covid-19 vaccine
Shares in Bavarian Nordic surged at the start following the release of positive pre-clinical trial data for its Covid-19 vaccine candidate, ABNCoV2.
The Danish biotechnology outfit said follow-up data from the study on its capsid virus like particle vaccine had confirmed that it induced neutralising antibodies against SARS-CoV-2, the virus responsible for Covid-19.
Indeed, the two high dose regimen without adjuvant, or boosters, triggered a greater than 50-fold increase in antibody levels in comparison to convalescent human samples.
Furthermore, when "challenged" with SARS-Cov-2, virus load was significantly reduced in all vaccinated groups and "no virus could be detected at any timepoint in the majority of the subjects vaccinated with two high doses of ABNCoV2."
As of 1446 GMT, shares of Bavarian Nordic were trading up by 7.43% to DKK217, having earlier in the session come within a whisker of its more than three-year highs of DKK261.0, after surging to DKK247.